Research programme: siRNA therapeutics - sanofi-aventis/TraversaAlternative Names: PTD-DRBD
Latest Information Update: 16 Jul 2016
At a glance
- Originator sanofi-aventis; Traversa Therapeutics
- Developer Sanofi; Traversa Therapeutics
- Mechanism of Action RNA interference
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Undefined in USA (Parenteral)
- 25 Mar 2010 Early research in Undefined indication in USA (Parenteral)